A hallmark of the CWRU/UHC research enterprise is a strong emphasis on international biomedical research with a particular interest in developing countries. The sixteen-year collaboration with Ugandan government and research facilities has fostered seminal studies of TB and HIV/AIDS. A major limitation to new initiatives in the developing world is the lack of state-of-the-art laboratory facilities on site. The longstanding research relationship between CWRU, the government of Uganda and Makerare University has resulted in the development of an extensive research infrastructure in Uganda. To facilitate sharing of these resources and to promote/support new research initiatives, all laboratory facilities and services associated with HIV/AIDS research are now being administered by the CWRU/UHC CFAR Uganda Laboratory Core with the following objectives: ? provide comprehensive laboratory services to facilitate HIV/AIDS-related research projects of CFAR investigators ? advertise these services, process requests, and coordinate research-based assays through the Uganda Laboratory Core ? provide a mechanism for training of Ugandan scientists in collaboration with CWRU and Fogarty AIDS Training Grant Moving forward, the Ugandan Laboratory Core seeks to: ? develop new assays to meet the needs of the CFAR investigators and improve the quality of HIV/AIDS research in Uganda ? continue to engage Ugandan scientists/clinicians in research collaboration with CFAR members by promoting training scholarships, sponsoring workshops and meetings

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI036219-15S1
Application #
7933416
Study Section
Special Emphasis Panel (ZAI1-AR-A (J3))
Project Start
2009-08-17
Project End
2010-03-31
Budget Start
2009-08-17
Budget End
2010-03-31
Support Year
15
Fiscal Year
2009
Total Cost
$113,447
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Mbonye, Uri; Wang, Benlian; Gokulrangan, Giridharan et al. (2018) Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem 293:10009-10025
Sayin, Ismail; Radtke, Andrea J; Vella, Laura A et al. (2018) Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med 215:1531-1542
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Martinez, Leonardo; Shen, Ye; Handel, Andreas et al. (2018) Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respir Med 6:276-286
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Kityo, Cissy; Makamdop, Krystelle Nganou; Rothenberger, Meghan et al. (2018) Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest 128:2763-2773

Showing the most recent 10 out of 539 publications